[go: up one dir, main page]

NO20075295L - Injiserbare sammensetninger av nanopartikulaere immunosuppressive forbindelser - Google Patents

Injiserbare sammensetninger av nanopartikulaere immunosuppressive forbindelser

Info

Publication number
NO20075295L
NO20075295L NO20075295A NO20075295A NO20075295L NO 20075295 L NO20075295 L NO 20075295L NO 20075295 A NO20075295 A NO 20075295A NO 20075295 A NO20075295 A NO 20075295A NO 20075295 L NO20075295 L NO 20075295L
Authority
NO
Norway
Prior art keywords
nanoparticulate
injectable
sirolimus
relates
composition
Prior art date
Application number
NO20075295A
Other languages
English (en)
Inventor
Gary Liversidge
Scott Jenkins
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of NO20075295L publication Critical patent/NO20075295L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en injiserbar nanopartikulær immunosuppresivtmiddel sammensetning for å danne et subkutant eller intramuskulært depot. Oppfinnelsen angår også en injiserbar sammensetning av nanopartikulært tacrolimus og/eller sirolimus som eliminerer behovet for å anvende polyoksyl 60 hydrogenert kastorolje (HCO-60) og/eller polysorbat 80 som et løselighetsfremmende middel. Oppfinnelsen beskriver ytterligere en fremgangsmåte for fremstilling av en injiserbar nanopartikulær tacrolimus og/eller sirolimus sammensetning og angår ogå fremgangsmåter for behandling ved anvendelse av de injiserbare nanopartikulære formuleringene som innbefatter tacrolimus, sirolimus eller kombinasjon derav for et subkutant eller intramuskulært depot for profylakse av organrejeksjon og for behandling av psoriasis eller andre immunsykdommer.
NO20075295A 2005-03-17 2007-10-16 Injiserbare sammensetninger av nanopartikulaere immunosuppressive forbindelser NO20075295L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66269205P 2005-03-17 2005-03-17
PCT/US2006/009510 WO2006101972A2 (en) 2005-03-17 2006-03-16 Injectable compositions of nanoparticulate immunosuppressive compounds

Publications (1)

Publication Number Publication Date
NO20075295L true NO20075295L (no) 2007-11-29

Family

ID=36954386

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075295A NO20075295L (no) 2005-03-17 2007-10-16 Injiserbare sammensetninger av nanopartikulaere immunosuppressive forbindelser

Country Status (14)

Country Link
US (1) US20060210638A1 (no)
EP (1) EP1868576A2 (no)
JP (1) JP2008533165A (no)
KR (1) KR20070121758A (no)
CN (1) CN101175481A (no)
AU (1) AU2006227623B2 (no)
BR (1) BRPI0606282A2 (no)
CA (1) CA2601312A1 (no)
EA (1) EA200701998A1 (no)
IL (1) IL185952A0 (no)
MX (1) MX2007011494A (no)
NO (1) NO20075295L (no)
WO (1) WO2006101972A2 (no)
ZA (1) ZA200708458B (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
CN1859909B (zh) * 2003-08-29 2011-04-06 生命周期药物公司 含有他克莫司的固态分散体
BRPI0414000B8 (pt) 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
ES2691646T3 (es) 2005-07-15 2018-11-28 Micell Technologies, Inc. Revestimientos poliméricos que contienen polvo de fármaco de morfología controlada
US8852625B2 (en) 2006-04-26 2014-10-07 Micell Technologies, Inc. Coatings containing multiple drugs
EP2343053A1 (en) 2006-05-30 2011-07-13 Elan Pharma International Limited Nanoparticulate posaconazole formulations
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US20080138405A1 (en) * 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
CA3027598C (en) 2007-01-10 2020-07-21 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
CA3201293A1 (en) * 2007-03-07 2008-09-12 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
US20100166869A1 (en) * 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
CN101815540B (zh) 2007-05-25 2015-08-19 米歇尔技术公司 用于医疗器材涂层的聚合物膜
PL2167033T4 (pl) 2007-05-30 2018-08-31 Veloxis Pharmaceuticals A/S Podawana raz dziennie doustna postać dawkowania zawierająca takrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
AU2008260447B2 (en) * 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
US20090130210A1 (en) * 2007-09-11 2009-05-21 Raheja Praveen Pharmaceutical compositions of sirolimus
EA020655B1 (ru) 2008-04-17 2014-12-30 Миселл Текнолоджиз, Инк. Стенты, имеющие биорассасывающиеся слои
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
EP2365802B1 (en) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules of rapamycin and use for treating cancer
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
EP3366326A1 (en) 2009-04-17 2018-08-29 Micell Technologies, Inc. Stents having controlled elution
CN101897964B (zh) * 2009-04-27 2013-04-10 中国农业大学 一种预防自身免疫疾病的药物
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
WO2011100975A2 (en) * 2010-02-17 2011-08-25 Lifecycle Pharma A/S Stabilized tacrolimus composition
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
EP2560576B1 (en) 2010-04-22 2018-07-18 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
CN103501812A (zh) 2011-04-29 2014-01-08 西莱克塔生物科技公司 用于过敏症治疗的致耐受性合成纳米载体
US10464100B2 (en) 2011-05-31 2019-11-05 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
WO2013012689A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
US8716363B2 (en) 2011-09-28 2014-05-06 Globus Medical, Inc. Biodegradable putty compositions and implant devices, methods, and kits relating to the same
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
MX375992B (es) 2012-11-08 2025-03-07 Univ Yamaguchi Agente terapeutico para trastornos de queratoconjuntivitis.
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
KR20150123838A (ko) * 2013-03-04 2015-11-04 브이티브이 테라퓨틱스 엘엘씨 안정한 글루코키나제 활성화제 조성물
US11039943B2 (en) 2013-03-12 2021-06-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
CA2910584A1 (en) * 2013-05-03 2014-11-06 Selecta Biosciences, Inc. Use of immunosuppressants attached to synthetic nanocarriers to enhance levels of cd4+ regulatory t cells
CA2912387C (en) 2013-05-15 2019-04-16 Micell Technologies, Inc. Bioabsorbable biomedical implants
CA2913005C (en) 2013-05-22 2021-08-10 Yamaguchi University Inhibitor for retinochoroidal disorders
CN113768881A (zh) 2013-10-08 2021-12-10 人工智能治疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
CA3206208A1 (en) 2013-12-31 2015-07-09 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
BR112016018365A2 (pt) * 2014-02-11 2017-08-08 Lam Therapeutics Inc Formulação farmacêutica aerossol, na forma de um pó seco para distribuição pulmonar, seus usos, forma de dosagem unitária, embalagem ou kit farmacêutico, e dispositivo de distribuição de pó seco
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CA2944075C (en) 2014-04-04 2022-06-28 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2017019214A1 (en) 2015-07-29 2017-02-02 Musc Foundation For Research Development Donor organ pre-treatment formulation
CN105267146B (zh) * 2015-11-25 2018-03-13 华北制药集团新药研究开发有限责任公司 一种无菌他克莫司纳米混悬滴眼液的制备方法
MY200642A (en) 2016-06-08 2024-01-08 Clementia Pharmaceuticals Inc Method for treating heterotopic ossification
EP3541380B1 (en) 2016-11-16 2021-12-15 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (mo)
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
EP3592389B1 (en) 2017-03-11 2025-05-07 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CA3070251A1 (en) 2017-08-24 2019-02-28 Jiangsu Hengrui Medicine Co., Ltd. Injectable pharmaceutical composition containing meloxicam, and preparation method therefor
CN108383856B (zh) * 2018-05-25 2020-03-27 中国医学科学院生物医学工程研究所 他克莫司纳米晶及其人工泪液复合物与制备方法
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
US20200038560A1 (en) * 2018-07-31 2020-02-06 Cook Medical Technologies Llc Limus coatings and methods of use thereof
CN112791066B (zh) * 2019-11-13 2024-04-02 鲁南制药集团股份有限公司 一种注射用西罗莫司缓释微球及其制备方法
CN111450064A (zh) * 2020-04-09 2020-07-28 广州中医药大学(广州中医药研究院) 基于超临界反溶剂法制备西罗莫司包覆颗粒的方法及其制得的西罗莫司包覆颗粒和应用
EP4014963A1 (en) 2020-12-16 2022-06-22 Medincell Pharmaceutical composition
US20240226126A1 (en) * 2021-06-16 2024-07-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions for treatment of psoriasis
JP2024536879A (ja) 2021-09-27 2024-10-08 ファーマシェン エス．エー． タクロリムスを含む薬学的製剤、その調製のための方法、および使用
GB2612779A (en) 2021-11-10 2023-05-17 Pharmathen Sa Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use
CN114642663A (zh) * 2022-03-29 2022-06-21 江苏杜瑞制药有限公司 一种稳定的他克莫司药物组合物及其制备方法和应用
CN117797093A (zh) * 2024-02-29 2024-04-02 中国农业科学院农业环境与可持续发展研究所 一种以大环内酯类药物为活性成分的兽用口服纳米液体制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5194378A (en) * 1991-01-28 1993-03-16 Merck & Co., Inc. Process for producing fk-506
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
ATE319432T1 (de) * 2000-12-22 2006-03-15 Baxter Int Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen
US6780324B2 (en) * 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
EP2283864A1 (en) * 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
AU2003292137A1 (en) * 2002-11-29 2004-06-23 Maria Grazia Roncarolo Rapamycin and il-10 for the treatment of immune diseases
MXPA05012467A (es) * 2003-05-19 2006-02-22 Baxter Int Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
CN1859909B (zh) * 2003-08-29 2011-04-06 生命周期药物公司 含有他克莫司的固态分散体
BRPI0414000B8 (pt) * 2003-08-29 2021-05-25 Lifecycle Pharma As composição farmacêutica sólida oral de liberação prolongada contendo tacrolimus na forma de uma dispersão sólida, forma de dosagem, e, uso da composição farmacêutica
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤

Also Published As

Publication number Publication date
EA200701998A1 (ru) 2008-02-28
KR20070121758A (ko) 2007-12-27
AU2006227623A1 (en) 2006-09-28
CN101175481A (zh) 2008-05-07
BRPI0606282A2 (pt) 2009-06-09
CA2601312A1 (en) 2006-09-28
ZA200708458B (en) 2009-05-27
JP2008533165A (ja) 2008-08-21
EP1868576A2 (en) 2007-12-26
AU2006227623B2 (en) 2011-10-20
IL185952A0 (en) 2008-01-06
WO2006101972A3 (en) 2006-12-07
WO2006101972A2 (en) 2006-09-28
MX2007011494A (es) 2007-12-06
US20060210638A1 (en) 2006-09-21

Similar Documents

Publication Publication Date Title
NO20075295L (no) Injiserbare sammensetninger av nanopartikulaere immunosuppressive forbindelser
DK1809329T3 (da) Vedvarende lokalanæstesisammensætning indeholdende saib
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
ECSP045073A (es) Nuevos derivados de piperazina
WO2003066629A3 (en) Heteroaryl compounds useful as inhibitors of gsk-3
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
EP4349327A3 (en) Emulsion formulations of multikinase inhibitors
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
WO2015058163A3 (en) Heteromaromatic compounds useful for the treatment of prolferative diseases
MX2008010671A (es) Derivados de cinolina como inhibidores de fosfodiesterasa 10.
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
ATE492278T1 (de) Verbindungen gegen entzündungen und immun- relevante verwendungen
EA201001371A1 (ru) Конденсированные пиримидиноновые соединения как модуляторы trpv3
ECSP088563A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
ATE430746T1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
MA29498B1 (fr) Derives de pyrazolopyridine en tant qu'inhibiteurs de recepteur kinase beta-adrenergique 1
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
JP2016505016A5 (no)
WO2009037542A3 (en) Spirocyclic compounds as stearoyl coa desaturase inhibitors
UY28805A1 (es) Derivados de 1,6-naftiridina y 1,8-naftiridina y su uso par tratar la diabetes y trastornos relacionados
ATE538124T1 (de) Imidazokondensierte tricyclische verbindungen auf thiazoloä4,5-büpyridin-basis und pharmazeutische zusammensetzungen damit
CL2008003332A1 (es) Compuestos derivados de ciclopentano sustituido, como agentes hipotensores oculares; composicion oftalmologicamente aceptable; y uso para el tratamiento del glaucoma.
WO2018106794A3 (en) Compositions and methods relating to molecular cerium-oxide nanoclusters
WO2007041076A3 (en) 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application